Does coronary vasodilation after adenosine override endothelin-1-induced coronary vasoconstriction?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 1, 2007, Pages

  Loghin, Catalin ^a   Sdringola, Stefano ^a   Gould, K Lance ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Coronary endothelial dysfunction; Positron emission tomography imaging

Indexed keywords

ADENOSINE; ENDOTHELIN 1; RUBIDIUM 82;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC IMAGING; DOG; FEMALE; HEART MUSCLE PERFUSION; IMAGING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADENOSINE; ANIMALS; ARTIFACTS; CORONARY VESSELS; DOGS; DRUG INTERACTIONS; ENDOTHELIN-1; FEMALE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRA-ARTERIAL; MALE; POSITRON-EMISSION TOMOGRAPHY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 33846232734     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00818.2006     Document Type: Article

References (31)

1. Camsarl A, Pekdemir H, Cicek D, Polat G, Akkus MN, Doven O, Cin VG, Katlrclbasl T, Parmakslz T. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 67: 1022-1028, 2003.
2. Cannan CR, Burnett JC Jr, Brandt RR, Lerman A. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation 92: 3312-3317, 1995.
3. Chu A, Chambers DE, Lin CC, Kuehl WD, Cobb FR. Nitric oxide modulates epicardial coronary basal vasomotor tone in awake dogs. Am J Physiol Heart Circ Physiol 258: H1250-H1254, 1990.
4. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 92: 3337-3349, 1995.
5. Demer LL, Gould KL, Goldstein RA, Kirkeeide RL, Mullani NA, Smalling RW, Nishikawa A, Merhige ME. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation 79: 825-835, 1989.
6. Goodwin AT, Yacoub MH. Role of endogenous endothelin on coronary flow in health and disease. Coron Artery Dis 12: 517-525, 2001.
7. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary stenosis. Instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 33: 87-94, 1974.
8. Gould KL. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation. I. Physiologic basis and experimental validation. Am J Cardiol 41: 267-278, 1978.
9. Gould KL, Schelbert HR, Phelps ME, Hoffman EJ. Noninvasive assessment of coronary stenoses with myocardial perfusion imaging during pharmacologic coronary vasodilatation. V. Detection of 47 percent diameter coronary stenosis with intravenous nitrogen-13 ammonia and emission-computed tomography in intact dogs. Am J Cardiol 43: 200-208, 1979.
10. Gould KL. Coronary Artery Stenosis and Reversing Atherosclerosis (2nd ed.). London: Arnold, 1999.
11. Gould KL, Nakagawa Y, Nakagawa K, Sdringola S, Hess MJ, Haynie M, Parker N, Mullani N, Kirkeeide R. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base-to-apex myocardial perfusion abnormalities by noninvasive positron emission tomography. Circulation 101: 1931-1939, 2000.
12. Gould KL, Kirkeeide RL, Buchi M. Coronary flow reserve as a physiologic measure of stenosis severity. J Am Coll Cardiol 15: 459-474, 1990.
13. Hoffmann E, Assennato P, Donatelli M, Colletti I, Valenti TM. Plasma endothelin-1 levels in patients with angina pectoris and normal coronary angiograms. Am Heart J 135: 684-688, 1998.
14. Ihling C, Bohrmann B, Schaefer HE, Technau-Ihling K, Loeffler BM. Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis: novel targets for pharmacotherapy in atherosclerosis. Curr Vasc Pharmacol 2: 249-258, 2004.
15. Johnson NP, Gould KL. Clinical evaluation of a new concept: resting myocardial perfusion heterogeneity quantified by markovian analysis of PET identifies coronary endothelial dysfunction and early atherosclerosis in 1,034 subjects. J Nucl Med 46: 1427-1437, 2005.
16. Juhasz-Nagy A, Kekesi V, Fazekas L, Merkely B, Toth M. Uneven flow distribution in the heart induced by endothelin. Adv Exp Med Biol 471: 247-256, 1999.
17. Loghin C, Sdringola S, Gould KL. Common artifacts in PET myocardial perfusion images due to attenuation-emission misregistration: clinical significance, causes, and solutions. J Nucl Med 45: 1029-1039, 2004.
18. Loscalzo J, Vita JA. Ischemia, hyperemia, exercise, and nitric oxide. Complex physiology and complex molecular adaptations. Circulation 90: 2556-2559, 1994.
19. MacCarthy PA, Pegge NC, Prendergast BD, Shah AM, Groves PH. The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol 37: 137-143, 2001.
20. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 53: 2060-2066, 2004.
21. Nakagawa Y, Nakagawa K, Sdringola S, Mullani N, Gould KL. A precise, three-dimensional atlas of myocardial perfusion correlated with coronary arteriographic anatomy. J Nucl Cardiol 8: 580-590, 2001.
22. Parker JD, Thiessen JJ. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol 286: H1141-H1145, 2004.
23. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 95: 1747-1755, 1995.
24. Schachinger V, Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in vivo: importance of baseline vasomotor tone in atherosclerosis. Circulation 92: 2087-2094, 1995.
25. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens 14: 83S-89S, 2001.
26. Sdringola S, Patel D, Gould KL. High prevalence of myocardial perfusion abnormalities on positron emission tomography in asymptomatic persons with a parent or sibling with coronary artery disease. Circulation 103: 496-501, 2001.
27. Sdringola S, Nakagawa K, Nakagawa Y, Yusuf SW, Boccalandro F, Mullani N, Haynie M, Hess MJ, Gould KL. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol 41: 263-272, 2003.
28. Shiode N, Morishima N, Nakayama K, Yamagata T, Matsuura H, Kajiyama G. Flow-mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis. J Am Coll Cardiol 27: 304-310, 1996.
29. Tousoulis D, Davies G, Lefroy DC, Haider AW, Crake T. Variable coronary vasomotor responses to acetylcholine in patients with normal coronary arteriograms: evidence for localized endothelial dysfunction. Heart 75: 261-266, 1996.
30. Wainstein MV, Goncalves SC, Zago AJ, Zenker R, Burttet R, Couto Gde B, Tomazi F, Ribeiro JP. Plasma endothelin-1 levels after coronary stenting in humans. Am J Cardiol 92: 1211-1214, 2003.
31. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 37: 1701-1712, 1996.